HeartBeam Inc. (NASDAQ: BEAT) will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call will also provide updates on key strategic growth initiatives, including the limited commercial launch and progress on its 12-lead ECG extended wear patch. A press release detailing the results will be issued prior to the call.
The company is a medical technology firm focused on transforming cardiac care through advanced cardiac insights. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever a patient is located to deliver actionable heart intelligence.
For business and technology leaders monitoring the intersection of healthcare innovation and digital transformation, HeartBeam's progress signals a shift toward decentralized, data-driven cardiac care. The technology enables physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of traditional medical facilities. This could potentially reduce healthcare system burdens and improve patient outcomes through earlier intervention.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received FDA clearance in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The intended use of its technology is detailed in the company's Cleared Indications for Use available at https://www.heartbeam.com/indications.
The upcoming conference call represents a critical update point for investors and industry observers tracking the commercialization of this breakthrough technology. The limited commercial launch of the 12-lead ECG extended wear patch will be particularly significant, as it represents the transition from regulatory approval to market implementation. The technology's potential to redefine cardiac health management by enabling comprehensive monitoring outside clinical settings could create new business models in remote patient monitoring and telehealth services.
For leaders in the technology sector, HeartBeam's approach demonstrates how advanced signal processing and miniaturized hardware can converge to solve complex medical challenges. The company's progress also highlights the growing importance of FDA-cleared digital health technologies that bridge the gap between consumer wearables and clinical-grade medical devices. As cardiovascular disease remains a leading cause of mortality worldwide, technologies that enable earlier detection and continuous monitoring could have substantial impact on global health outcomes and healthcare economics.
The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
